Pew Responds to White House's Drug Pricing Blueprint Information Request

Comments address administration’s questions on how federal, manufacturer programs affect spending

The White House's Drug Pricing Blueprint

The Pew Charitable Trusts sent a letter July 16 to the U.S. Department of Health and Human Services, offering comments on the Trump administration’s Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Request for Information (RFI).

Pew’s response to the RFI addresses the following topics:

  • Federal program incentives.
  • Drug pricing structures and incentives.
  • Proposals to reform the Medicare Part B Competitive Acquisition Program.
  • Price reporting requirements and incentive structures.
  • Cost-shifting and cross-subsidization.
  • Generic drug pricing and development.
  • Pharmacy benefit managers and rebates.
  • 340B Drug Pricing Program.
  • Patient cost-sharing.
America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up